The Company

Nano Safe Coatings (NSC) was founded as a technology-development company to take advantage of and to commercialize patent and patent-pending technologies to control biofilms on medical devices and medical-related products.

A team of researchers at Ryerson University in Toronto, Canada took a long-established technology that has been around since the mid-70s, and improved the anchoring mechanism so it permanently attaches to various substrates including metals, plastics and fabrics. The technologies are perfectly suited for medical device manufacturers, wound care products, medical-related products, and hospital environments where the potential of Healthcare-Acquired Infections (HAI) is greatest.

These technologies change the paradigm for controlling biofilms, infectious organisms, and drug resistant microbes associated with medical devices and medical-related products. NSC technologies modify metals, plastics and fabrics, and make them resistant to the attachment and propagation of non-eukaryotic organisms without adverse affects to humans, materials or the environment.

NSC alters medical devices and products in ways that enhance the overall performance of the treated surfaces. Covalent bonding occurs by using UV for plastics and heat catalysis for metals. This produces a durable coating of microbe killing nano-networks, which provides mechanical microbial-killing control that exceeds what is currently available in the marketplace. In addition, the process avoids the negative effects experienced by leaching technologies and other microbe-killing products that are available.

Currently there is an unmet need for safe and effective antimicrobial technology. NSC has the solution to this dilemma, and is committed to reducing HAI and other life-threating conditions commonly experienced in the healthcare environment.
Our Eight Pillars for Success and our efforts to date have focused on:

  1. Establish a lean corporate structure staffed by experienced experts in all aspects of the customers' products and needs, marketplace channels, business venture, antimicrobial technologies and chemistries, and regulatory requirements.
  2. Establish a robust patent portfolio issued and pending in key industrialized countries. The scope of these patents are focused on the composition of matter, the process of manufacturing, and two classes of chemicals that provide a durable bond to metals, plastics and fabrics, while furnishing superior antimicrobial/anti-biofilm protection.
  3. The chemical characterization of “best in class” technologies from the portfolio, and optimizing the synthesis pathways.
  4. Secure a manufacturing relationship with global-scale ISO quality manufacturers.
  5. Develop application technologies linked to multiple application strategies.
  6. Build a robust database of the antimicrobial/anti-biofilm properties on treated materials by using Good Lab Practice testing conditions, and in most cases achieving up to a six-log or greater reduction in three hours.
  7. Build a FDA Device Master File (DMF) that our customers can cite for qualifying our treatment as a modifier of their devices under the 510(k) or de nova processes.
  8. Conduct testing in the marketplace by using a business approach and establishing joint development relationships with a variety of customers to carry out proof-of-concept testing while developing a value definition, and creating steps to commercialization.